114 related articles for article (PubMed ID: 38660850)
1. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract][Full Text] [Related]
2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
3. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
4. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
5. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
6. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
[TBL] [Abstract][Full Text] [Related]
8. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
9. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
10. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
12. In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. Italian Lymphoma Study Group (GISL).
Vecchi A; Cavanna L; Avanzini P; Callea V; Velardi A; Albi N; Tartoni P; Bensi L; Valentini P; Longo R; Sacchi S
Eur J Haematol; 1996 Jul; 57(1):33-7. PubMed ID: 8698128
[TBL] [Abstract][Full Text] [Related]
13. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.
Peest D; Leo R; Bloche S; Hein R; Stannat-Kiessling S; Tschechne B; Fett W; Harms P; Hoffmann L; Bartl R
Br J Haematol; 1995 Feb; 89(2):328-37. PubMed ID: 7873383
[TBL] [Abstract][Full Text] [Related]
14. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
19. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.
Zloza A; Dharmadhikari ND; Huelsmann EJ; Broucek JR; Hughes T; Kohlhapp FJ; Kaufman HL
Cancer Immunol Immunother; 2017 Jan; 66(1):9-16. PubMed ID: 27757560
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
